Anticoagulants Market size to surpass $80bn by 2030

Anticoagulants Market size is set to reach USD 80 billion by 2030, as per a new market research report published by Global Market Insights Inc.
 

The increasing awareness and acceptance of novel oral anticoagulants (NOACs) in developing nations will create numerous business opportunities for the drug manufacturers. The benefits associated with NOACs include shorter half-life, rapid onset action, and predictable pharmacokinetic action.
 

Governments across the world are launching various initiatives to promote the awareness regarding cardiac health. For instance, the Government of Australia launched the National Strategic Action Plan for Heart Disease and Stroke in September 2021. The plan will focus on the prevention and early detection of heart diseases as well as providing the right support through highly trained medical professionals. Such initiatives will fuel the demand for anticoagulants for heart disease patients.
 

Rising prevalence of deep vein thrombosis to drive factor Xa inhibitor demand

Factor Xa inhibitor segment will cross USD 48 billion by 2030. These drugs prevent blood clot formation by blocking the function of the clotting factor Xa. The incidence of chronic diseases, such as deep vein thrombosis (DVT) and acute pulmonary embolism (PE) is rising at a disturbing rate every year. According to the CDC, 60,000-100,000 American citizens die from DVT/PE each year. This aspect, along with the growing availability of factor Xa inhibitors, will spur the market trends.
 

Browse key industry insights spread across 181 pages with 227 market data tables & 18 figures & charts from the report, “Anticoagulants Market Size By Drug Class (Factor Xa Inhibitors, Heparin, Warfarin, Direct Thrombin Inhibitors), By Route of Administration (Oral, Injectables), By Application (Venous Thromboembolism, Atrial Fibrillation/Flutter, Coronary Artery Disease), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2030” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/anticoagulants-market
 

Injectable drugs to witness consistent surge in consumption

Injectable anticoagulants industry share will record more than 9% CAGR during the forecast period 2022-2030. The most used injectable anticoagulants include low molecular weight heparins, heparin, bivalirudin, danaparoid, and lepirudin. The demand for low molecular weight heparins is gaining momentum among end-users as they possess a highly effective blood thinning action, which takes place within two to three doses. These injectables are used as a bridging therapy for patients that have started taking oral anticoagulants, such as warfarin.
 

High occurrence of venous thromboembolism to augment anticoagulants use

Anticoagulants market value from the venous thromboembolism (VTE) segment is set to exceed USD 6 billion by 2030. The public awareness regarding thrombosis has increased considerably, thanks to several government-backed initiatives and campaigns. The overall prevalence of venous thrombosis is growing at a worrying rate as well. Around 10 million people worldwide are affected by venous thromboembolism (VTE) every year. This scenario will be key to boosting the production of anticoagulants to reduce the mortality rate and extend the benefits of these medicines to as many patients as possible.
 

Retail pharmacies to observe robust sales of anticoagulant products

Anticoagulants industry share from the retail pharmacy segment is estimated to be more than USD 25 billion by 2030. Increasing utilization of anticoagulant drugs in the treatment of various diseases will accelerate the segment expansion. Many retail brand owners are planning to expand their pharmacy chains to cater to growing customer needs. Retail pharmacies allow a greater number of people access to required drugs, along with the availability of anticoagulants from different pharmaceutical brands.
 

Growing diabetic population expands APAC anticoagulants industry

Asia Pacific anticoagulants market will showcase commendable expansion over the coming years. More people across the region are becoming aware about the importance of going for regular health check-ups. The region also has a vast presence of reputed pharmaceutical companies, which will positively affect the market forecast. The risk of diabetes and obesity is increasing among the regional population. As per a report by the Indian Council of Medical Research (ICMR), as of 2022, the country has witnessed a 150% increase in diabetes cases over the last 30 years. Since diabetics are at a higher risk of contracting atrial fibrillation, the demand for anticoagulants is rising.
 

Competitors adopt effective growth strategies to reinforce market stance

Amphastar Pharmaceuticals, Inc., Bristol-Myers Squibb, Bayer AG, Boehringer Ingelheim, Daiichi Sankyo Company, Johnson and Johnson, Shenzhen Hepalink, Sanofi, Pfizer, Rovi, and United Therapeutics, among others, are the leading companies in the anticoagulants market. These firms are seeking partnership agreements, mergers & acquisitions, and product developments to increase their global visibility.
 

For example, in March 2019, Amphastar announced that it received the U.S. FDA’s approval for its Enoxaparin sodium injection 300mg/3mL (100mg/mL) multiple dose vial (MDV) indicated for prophylaxis of deep vein thrombosis. This launch assisted the company in widening its customer base and strengthening its market position.